Who are BF-200 ALA 10%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ameluz 10% Topical Gel, TOOKAD VTP, BF-200 ALA cream, Physician's Choice SOC, c-PDT, NDL-PDT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bf-200-ala-10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BF-200 ALA 10% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BF-200 ALA 10% (BF-200 ALA 10%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photodynamic therapy agent. Area: Dermatology/Oncology.

phase 2 Photodynamic therapy agent Protoporphyrin IX (photosensitizer) Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BF-200 ALA 10% (BF-200 ALA 10%) — Biofrontera Bioscience GmbH. BF-200 ALA is a topical 5-aminolevulinic acid (ALA) formulation that generates reactive oxygen species upon light activation to destroy abnormal skin cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BF-200 ALA 10% TARGET	BF-200 ALA 10%	Biofrontera Bioscience GmbH	phase 2	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)
Ameluz 10% Topical Gel	Ameluz 10% Topical Gel	Psoriasis Treatment Center of Central New Jersey	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)
TOOKAD VTP	TOOKAD VTP	Steba Biotech S.A.	marketed	Photodynamic therapy agent	Vascular endothelial cells (non-receptor mediated phototoxicity)
BF-200 ALA cream	BF-200 ALA cream	Joint Authority for Päijät-Häme Social and Health Care	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer generated from aminolevulinic acid)
Physician's Choice SOC	Physician's Choice SOC	Rakuten Medical, Inc.	phase 3	X-ray activated photodynamic therapy agent
c-PDT	c-PDT	Galderma R&D	phase 3	Photodynamic therapy agent
NDL-PDT	NDL-PDT	Galderma R&D	phase 3	Photodynamic therapy agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photodynamic therapy agent class)

Galderma R&D · 3 drugs in this class
DUSA Pharmaceuticals, Inc. · 2 drugs in this class
Biofrontera Bioscience GmbH · 2 drugs in this class
Steba Biotech S.A. · 2 drugs in this class
National Cancer Center, Korea · 1 drug in this class
Photocure · 1 drug in this class
Psoriasis Treatment Center of Central New Jersey · 1 drug in this class
Joint Authority for Päijät-Häme Social and Health Care · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BF-200 ALA 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/bf-200-ala-10. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing